Compare ARK Genomic Revolution ETF (ARKG) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Kyndryl Holdings Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.8, while Kyndryl Holdings Inc trades at $12.45 (market cap $2.64B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | KD | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $39.78 |
52-Week Low | $23.09 | $10.59 |
Market Cap | — | $2.64B |
Enterprise Value | — | $4.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Kyndryl Holdings (KD) trades at $11.97, down 0.83% on the day, with technical indicators signaling a bearish trend. The company reported revenue of $15.06B in 2025, achieving a net income of $252M after three years of losses. Recent news includes leadership changes and legal investigations, while analyst consensus is mixed with a $14.33 price target. Cash flow improved to a net positive $236M in 2025, though debt levels remain elevated.
The outlook is cautious; profitability improvements and strategic partnerships offer potential upside, but legal risks and recent earnings misses pose significant challenges. Investors should weigh the low P/E of 14.08 against ongoing operational and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
